Accelerating Antibody Drug Development With Subdomain-Specific Affinity Chromatography

By Pim Hermans, Frank Detmers, Kevin Sleijpen, Simon Adema, Hendrik Adams, Elina Klijs, Anja Overweel, Paul Janszen, Jessica de Rooij & Laurens Sierkstra

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise. Affinity chromatography resins, specifically developed to bind antibody-subdomain regions, can provide an alternative solution in the purification process of these new formats. Thereby, advancing the commercial production of new antibody therapeutics.

Learn more about the CaptureSelect antibody subdomain-specific affinity resins and how they address the purification challenges in therapeutic antibody development.